At the Center for Gastrointestinal Oncology we treat a range of malignancies that occur within the gastrointestinal tract and gastrointestinal system. These diseases include colorectal, esophageal, stomach, pancreatic, small intestine, liver, neuroendocrine, gallbladder/bile duct, and anal carcinomas.

Our dual goals are to provide the best possible treatments to our patients and to develop new knowledge and new treatment paradigms that can be broadly applied to all patients with gastrointestinal cancers. A critical piece of our efforts to pursue these goals is our increasing use of new genomic and molecular testing of patients’ tumors as part of our care and our research.

SOG_6735_12_smOur Contributions

New efforts within Dana-Farber/Brigham and Women’s Center for Gastrointestinal Oncology are aiming to profile the DNA (or genome) of patients’ tumors. With these studies we are looking for specific DNA changes (mutations), as well as for other molecular changes that have implications for the potential of the tumor to be effectively treated by distinct therapies.

Learn More

The Latest Thinking

Dr. Bellmunt Shares KEYNOTE-045 Data for Pembrolizumab Versus Chemotherapy in Bladder Cancer Read More

Merck’s Keytruda succeeds in key bladder cancer trial Read More

Researchers identify early sign of pancreatic cancer Read More

157339113_smWhat to Expect

We view every patient as an individual, with unique needs and expectations. This understanding guides us in creating a treatment plan that takes your lifestyle and goals into account. As a new patient, you’ll have your tumors tested for molecular alterations, the results of which will help form the basis of your therapy.

Learn More